A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity

Hypertension

Volumn 51, Issue 3, 2008, Pages 742-748

  Dietz, Jessica D ^a   Du, Sarah ^a   Bolten, Charles W ^a   Payne, Maria A ^a   Xia, Chunsheng ^a   Blinn, James R ^a   Funder, John W ^b   Hu, Xiao ^a  

^a PFIZER INC   (United States)

^b HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Aldosterone; Calcium channel blockers; Dihydropyridine; Mineralocorticoid receptor antagonist

Indexed keywords

ALDOSTERONE; AMLODIPINE; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE DERIVATIVE; DILTIAZEM; EPITHELIAL SODIUM CHANNEL; EPLERENONE; FELODIPINE; ISRADIPINE; MINERALOCORTICOID RECEPTOR; MUTANT PROTEIN; NICARDIPINE; NIFEDIPINE; NIMODIPINE; NISOLDIPINE; NITRENDIPINE; PROTEIN SUBUNIT; RECEPTOR BLOCKING AGENT; VERAPAMIL;

ADRENALECTOMY; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; IC 50; IN VIVO STUDY; LIGAND BINDING; MALE; MOLECULAR MODEL; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; UPREGULATION;

ADRENALECTOMY; ALDOSTERONE; ANIMALS; CALCIUM CHANNEL BLOCKERS; DIHYDROPYRIDINES; DOSE-RESPONSE RELATIONSHIP, DRUG; EPITHELIAL SODIUM CHANNEL; MALE; MODELS, MOLECULAR; MUTATION; NIMODIPINE; PROTEIN BINDING; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, MINERALOCORTICOID;

EID: 39749199510     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.107.103580     Document Type: Article

References (39)

1. Rodgers PT. Combination drug therapy in hypertension: a rational approach for the pharmacist. J Am Pharm Assoc (Wash). 1998;38:469-479.
2. Sica DA. Current concepts of pharmacotherapy in hypertension: combination calcium channel blocker therapy in the treatment of hypertension. J Clin Hypertens (Greenwich). 2001;3:322-327.
3. Meredith PA, Elliott HL. Dihydropyridine calcium channel blockers: basic pharmacological similarities but fundamental therapeutic differences. J Hypertens. 2004;22:1641-1648.
4. Dendorfer A, Dominiak P, Schunkert H. ACE inhibitors and angiotensin II receptor antagonists. Handb Exp Pharmacol. 2005:407-442.
5. Flack JM, Oparil S, Pratt JH, Roniker B, Garthwaite S, Kleiman JH, Yang Y, Krause SL, Workman D, Saunders E. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J Am Coll Cardiol. 2003;41:1148-1155.
6. Williams GH, Burgess E, Kolloch RE, Ruilope LM, Niegowska J, Kipnes MS, Roniker B, Patrick JL, Krause SL. Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension. Am J Cardiol. 2004;93:990-996.
7. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ. 2003;326:1427.
8. Hultman ML, Krasnoperova NV, Li S, Du S, Xia C, Dietz JD, Lala DS, Welsch DJ, Hu X. The ligand-dependent interaction of mineralocorticoid receptor with coactivator and corepressor peptides suggests multiple activation mechanisms. Mol Endocrinol. 2005;19:1460-1473.
9. Li Y, Suino K, Daugherty J, Xu HE. Structural and biochemical mechanisms for the specificity of hormone binding and coactivator assembly by mineralocorticoid receptor. Mol Cell. 2005;19:367-380.
10. Bledsoe RK, Madauss KP, Holt JA, Apolito CJ, Lambert MH, Pearce KH, Stanley TB, Stewart EL, Trump RP, Willson TM, Williams SP. A ligand-mediated hydrogen bond network required for the activation of the mineralocorticoid receptor. J Biol Chem. 2005;280:31283-31293.
11. Sherman W, Day T, Jacobson MP, Friesner RA, Farid R. Novel procedure for modeling ligand/receptor induced fit effects. J Med Chem. 2006;49:534-553.
12. Hu X, Li S, McMahon EG, Lala DS, Rudolph AE. Molecular mechanisms of mineralocorticoid receptor antagonism by eplerenone. Mini Rev Med Chem. 2005;5:709-718.
13. Morel N, Buryi V, Feron O, Gomez JP, Christen MO, Godfraind T. The action of calcium channel blockers on recombinant L-type calcium channel alpha1-subunits. Br J Pharmacol. 1998;125:1005-1012.
14. Yiu SH, Knaus EE. Synthesis, calcium channel antagonist activity, and anticonvulsant activity of 3-ethyl 5-methyl 1,4-dihydro-2-[(2-hydroxyethoxy) methyl]-6-methyl-4-(2,3-dichlorophenyl)-3,5-pyridinedicarboxylate coupled to a 1-methyl-1,4-dihydropyridyl-3-carbonyl chemical delivery system. Arch Pharm (Weinheim). 1999;332:363-367.
15. Geller DS, Farhi A, Pinkerton N, Fradley M, Moritz M, Spitzer A, Meinke G, Tsai FT, Sigler PB, Lifton RP. Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. Science. 2000;289:119-123.
16. Epple HJ, Amasheh S, Mankertz J, Goltz M, Schulzke JD, Fromm M. Early aldosterone effect in distal colon by transcriptional regulation of ENaC subunits. Am J Physiol Gastrointest Liver Physiol. 2000;278:G718-G724.
17. Coric T, Hernandez N, Alvarez de la Rosa D, Shao D, Wang T, Canessa CM. Expression of ENaC and serum- and glucocorticoid-induced kinase 1 in the rat intestinal epithelium. Am J Physiol Gastrointest Liver Physiol. 2004;286:G663-G670.
18. Zhang QZ, Jiang XG, Wu CH. Distribution of nimodipine in brain following intranasal administration in rats. Acta Pharmacol Sin. 2004;25:522-527.
19. Kauppi B, Jakob C, Farnegardh M, Yang J, Ahola H, Alarcon M, Calles K, Engstrom O, Harlan J, Muchmore S, Ramqvist AK, Thorell S, Ohman L, Greer J, Gustafsson JA, Carlstedt-Duke J, Carlquist M. The threedimensional structures of antagonistic and agonistic forms of the glucocorticoid receptor ligand-binding domain: RU-486 induces a transconformation that leads to active antagonism. J Biol Chem. 2003;278:22748-22754.
20. Madauss KP, Grygielko ET, Deng SJ, Sulpizio AC, Stanley TB, Wu C, Short SA, Thompson SK, Stewart EL, Laping NJ, Williams SP, Bray JD. A structural and in vitro characterization of asoprisnil: a selective progesterone receptor modulator. Mol Endocrinol. 2007;21:1066-1081.
21. Katz AM, Leach NM. Differential effects of 1,4-dihydropyridine calcium channel blockers: therapeutic implications. J Clin Pharmacol. 1987;27:825-834.
22. Haws CW, Gourley JK, Heistad DD. Effects of nimodipine on cerebral blood flow. J Pharmacol Exp Ther. 1983;225:24-28.
23. Sakowitz OW, Unterberg AW. Detecting and treating microvascular ischemia after subarachnoid hemorrhage. Curr Opin Crit Care. 2006;12:103-111.
24. Rocha R, Stier CT Jr. Pathophysiological effects of aldosterone in cardiovascular tissues. Trends Endocrinol Metab. 2001;12:308-314.
25. Iwanami J, Mogi M, Okamoto S, Gao XY, Li JM, Min LJ, Ide A, Tsukuda K, Iwai M, Horiuchi M. Pretreatment with eplerenone reduces stroke volume in mouse middle cerebral artery occlusion model. Eur J Pharmacol. 2007;566:153-159.
26. Thulin T, Fagher B, Grabowski M, Ryding E, Elmqvist D, Johansson BB. Cerebral blood flow in patients with severe hypertension, and acute and chronic effects of felodipine. J Hypertens. 1993;11:83-88.
27. Landmark K, Forsman M, Lindberg K, Ryman T, Martmann-Moe K, Haaverstad S, Wiel S. Nitrendipine and mefruside in elderly hypertensives: effects on blood pressure, cardiac output, cerebral blood flow and metabolic parameters. J Hum Hypertens. 1995;9:281-285.
28. Pandita-Gunawardena ND, Clarke SE. Amlodipine lowers blood pressure without affecting cerebral blood flow as measured by single photon emission computed tomography in elderly hypertensive subjects. Age Ageing. 1999;28:451-457.
29. Blardi P, Urso R, De Lalla A, Volpi L, Perri TD, Auteri A. Nimodipine: drug pharmacokinetics and plasma adenosine levels in patients affected by cerebral ischemia. Clin Pharmacol Ther. 2002;72:556-561.
30. Hedner T, Elmfeldt D, Dahlof C, Sjogren E. Comparison of antihypertensive effect and pharmacokinetics of conventional and extended release felodipine tablets in patients with arterial hypertension. Drugs. 1987;34 Suppl 3:125-131.
31. Fujimura A, Ohashi K, Sugimoto K, Kumagai Y, Ebihara A. Chronopharmacological study of nitrendipine in healthy subjects. J Clin Pharmacol. 1989;29:909-915.
32. Toal CB. Formulation dependent pharmacokinetics- does the dosage form matter for nifedipine? J Cardiovasc Pharmacol. 2004;44:82-86.
33. Uchida S, Yamada S, Nagai K, Deguchi Y, Kimura R. Brain pharmacokinetics and in vivo receptor binding of 1,4-dihydropyridine calcium channel antagonists. Life Sci. 1997;61:2083-2090.
34. Hishikawa K, Luscher TF. Felodipine inhibits free-radical production by cytokines and glucose in human smooth muscle cells. Hypertension. 1998;32:1011-1015.
35. Jiang ZG, Shi XR, Guan BC, Zhao H, Yang YQ. Dihydropyridines inhibit acetylcholine-induced hyperpolarization in cochlear artery via blockade of intermediate-conductance calcium-activated potassium channels. J Pharmacol Exp Ther. 2007;320:544-551.
36. Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation. 2004;109:2054-2057.
37. Schupp M, Curtin JC, Kim RJ, Billin AN, Lazar MA. A widely used retinoic acid receptor antagonist induces peroxisome proliferator-activated receptor-gamma activity. Mol Pharmacol. 2007;71:1251-1257.
38. Wu J, Xia C, Meier J, Li S, Hu X, Lala DS. The hypolipidemic natural product guggulsterone acts as an antagonist of the bile acid receptor. Mol Endocrinol. 2002;16:1590-1597.
39. Huang W, Zhang J, Moore DD. A traditional herbal medicine enhances bilirubin clearance by activating the nuclear receptor CAR. J Clin Invest. 2004;113:137-143.